Earnings ·
BrainsWay Ltd. reported second quarter 2026 financial results and raised full-year guidance
BWAYBrainsway Ltd.
BrainsWay Ltd. reported second quarter 2026 financial results and raised full-year guidance. Revenue increased 35% to $17.1 million, while Adjusted EBITDA more than doubled year-over-year to $3.5 million with a 20% margin. The company shipped a record 125 Deep TMS systems in Q2, bringing the total installed base to approximately 1,949 units. Remaining performance obligations grew 30% to $80.4 million. Management raised FY 2026 revenue guidance to $68–$70 million and Adjusted EBITDA guidance to $13–$14 million. BrainsWay Ltd. operates in the medical device industry, developing noninvasive neurostimulation treatments for mental health disorders.